Study Costs. 6.1 The NYISO shall invoice on a monthly basis, and Requestor shall pay to the NYISO, the actual costs incurred by the NYISO to perform the Requested Economic Planning Study in accordance with the requirements in Sections 31.3.3.7, 31.3.3.8, and 31.3.3.9 of Attachment Y of the ISO OATT. This includes costs that the NYISO incurs at its discretion to use contractors or consultants, computing services, and costs that Transmission Owners may incur to supply study-related data at the NYISO’s request. Costs shall be computed on a time and materials basis in accordance with the rates set forth in Attachment B to this Agreement.
6.2 Requestor submitted an initial deposit of $25,000 with its Request Form in accordance with Section 31.3.3.2 of Attachment Y to the ISO OATT. The NYISO’s good faith estimate of the total cost of the Requested Economic Planning Study is $[ ]. The Parties acknowledge and agree that the actual total cost of the Requested Economic Planning Study may differ from this estimate. Upon execution of this Agreement, the ISO may require, at its discretion, and Requestor shall submit an additional deposit of $[ ] in accordance with Section 31.3.3.5 of Attachment Y of the ISO OATT. If Requestor modifies the scope of the Requested Economic Planning Study as initially specified in Attachment A to this Agreement, and does so in such a way as to increase the estimated total cost of the Requested Economic Planning Study, the NYISO may require, at its discretion, and the Requestor shall pay, an additional deposit to reflect that cost increase. The NYISO shall hold the study deposit(s) provided by Requestor in an interest-bearing account for which the interest earned will be associated with Requestor and shall be applied to study costs and subject to refund as described in Section 31.3.3.8 of Attachment Y of the ISO OATT.
6.3 Upon: (i) the completion of the Requested Economic Planning Study or the withdrawal of the Request Form due to the termination of this Agreement, and (ii) the ISO’s receipt of all final invoices from its consultants and contractors, computing services, and involved Transmission Owners, the ISO shall issue a final invoice to Requestor. Upon the ISO’s receipt of Requestor’s final payment for all outstanding invoiced amounts, the ISO shall refund to Requestor: (i) its study deposit(s) submitted to the ISO pursuant to Section 6.2 of this Agreement and Sections 31.3.3.2 and 31.3.3.5 of Attachment Y of the ISO OATT, less any amount that the ...
Study Costs. The costs for the sector-oriented or function-oriented training courses that are attended on the employer’s request are borne by the employer. Costs considered as such are tuition fees, exam fees, travel and accommodation expenses, and the costs of prescribed training materials.
Study Costs. 7.1 The NYISO shall charge, and Requestor shall pay, all reasonable costs actually incurred by the NYISO to perform or cause to be performed, the Additional Reliability Study. Such costs may include the cost of consultants and contractors retained by the NYISO and the cost, if any, incurred by Transmission Owner(s) to supply study-related data when requested to do so by the NYISO. Costs shall be computed on a time and materials basis in accordance with the rates set forth in Attachment B to this Agreement.
7.2 The initial deposit of $25,000 submitted by Requestor with its Request For Additional Reliability Study, shall be applied to the cost of the Additional Reliability Study. The NYISO’s good faith estimate of the total cost of the Additional Reliability Study is $[ ]. The Parties acknowledge and agree that the actual total cost of the Additional Reliability Study may differ from this estimate. Upon execution of this Agreement, Requestor shall submit an additional deposit of $[ ] which the NYISO shall also apply to the actual cost of the Additional Reliability Study. If Requestor modifies the scope of the Additional Reliability Study as initially specified in Attachment A to this Agreement, and does so in such a way as to increase the estimated total cost of the Additional Reliability Study, the NYISO may request, and the Requestor shall pay, an additional deposit to reflect that cost increase, which the NYISO shall also apply to the actual cost of the Additional Reliability Study.
7.3 Upon completion of the Additional Reliability Study, NYISO shall charge, and Requestor shall pay, all reasonable costs actually incurred by the NYISO for the Additional Reliability Study. Any difference between the total of the deposits submitted by Requestor and the actual cost of the Additional Reliability Study shall be paid by or refunded to Requestor, as appropriate, within thirty (30) days of the final invoice.
Study Costs. Except as expressly provided in Article 3, Migenix shall be solely responsible for all of the costs and expenses of the Clinical Trial.
Study Costs. 14.1. An employee who, at the expense of UT, is completing a study programme on the instructions of UT or at their own request, but has not yet completed it after compulsory redundancy, will be permitted to complete the study at the UT’s expense.
14.2. The obligation to reimburse study costs for a study requested by the employee can only arise if this obligation was specified in the decision on the request and the circumstances described in this decision occur. In accordance with the UT Employee Education and Study Regulations (Regeling opleidingen UT) in force, this obligation to repay can only apply for a study or education that is not relevant to their work.
Study Costs. 4.1 For avoidance of doubt, the BMS-Ono Parties and Exelixis shall share equally the Shared Costs for each Combined Therapy Trial in the Ono Territory (i.e. the BMS-Ono Parties shall be responsible for fifty percent (50%) of the Shared Costs and Exelixis shall be responsible for fifty percent (50%) of the Shared Costs) for each control arm and each double therapy arm (i.e., Cabozantinib + Nivolumab or Cabozantinib + Ipilimumab) of each Combined Therapy Trial in the Ono Territory, and the BMS-Ono Parties and Exelixis shall share the Shared Costs for each Combined Therapy Trial in the Ono Territory sixty seven (67%) / thirty-three percent (33%) (i.e., the BMS-Ono Parties shall be responsible for sixty-seven percent (67%) of the Shared Costs and Exelixis responsible for thirty-three percent (33%) of the Shared Costs) for each triple therapy arm (i.e., Cabozantinib + Nivolumab + Ipilimumab) of a Combined Therapy Trial in the Ono Territory, in accordance with Article 7 of the Collaboration Agreement.
4.2 BMS shall be the lead BMS-Ono Party for purposes of performing any required Shared Cost reconciliation and making and/or receiving reconciliation payments in accordance with the Collaboration Agreement. Payments made by BMS to Exelixis and amounts received by BMS from Exelixis shall be allocated and/or trued-up between BMS and Ono in accordance with the Ono-BMS Agreements.
Study Costs. 4.1 The Customer agrees to pay to Manitoba Hydro the actual costs for the performance by Manitoba Hydro of the Study and the preparation of the Study Report (the “Actual Study Costs”). The Customer shall pay to Manitoba Hydro, concurrent with the signing and delivery of this Agreement, the sum of • Dollars ($•) (plus applicable taxes) which sum represents an estimate of the Actual Study Costs (the “Estimated Study Costs”). The Customer hereby authorizes Manitoba Hydro to apply the funds representing the Estimated Study Costs toward payment of the Actual Study Costs as these costs are incurred. The Customer agrees to pay the amount of the Actual Study Costs which exceed the Estimated Study Costs, if any, within thirty (30) days of receipt of an invoice for such Actual Study Costs.
4.2 If after completion of the Study Report, or termination of this Agreement, the Estimated Study Costs exceeds the Actual Study Costs, Manitoba Hydro shall refund the excess amount to the Customer within thirty (30) days after delivery of the Study Report or within thirty (30) days of the withdrawal or termination of this Agreement, as the case may be.
Study Costs. Except as otherwise provided in Section 7.2.1, 7.2.3(b), 7.4 or 7.6, Gilead shall bear any internal or external costs or expenses incurred by Gilead in connection with its supply of the Gilead Compound for use in the Gilead Arm in accordance with this Agreement. Except as otherwise provided in this Agreement, as between the Parties, Company shall bear all internal and external costs and expenses associated with the conduct of the Study (including the Gilead Arm). [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.
Study Costs. For purposes of this Agreement, “Study Costs” means (a) the FTE Cost for the Sponsoring Party FTEs directly supporting a Combined Therapy Study where the Sponsoring Party does not engage a CRO for the conduct of such Combined Therapy Study, and (ii) the out-of-pocket costs reasonably incurred by each Party to Third Party clinical trial sites, CROs and other contractors and vendors for the conduct of the Combined Therapy Study (including out-of-pocket costs for sourcing any Other Therapy used in the Combined Therapy Study, project management, document management, monitoring and site management, specimen management, laboratory, imaging, investigator grants, site costs, Compound labeling and storage, electronic data capture (EDC), interactive voice response system (IVRS), cost of comparator drugs (as applicable in accordance with the applicable Protocol), consultants, contractors for the testing and screening of patients and lab costs). Study Costs shall also include the out-of-pocket costs of the PD-L1 Expression Testing (and any exploratory biomarker analysis to be conducted by BMS as specified in the Bioanalysis Plan), and the out-of-pocket costs of the Biomarker Testing (and any exploratory biomarker analysis to be conducted by the Company as specified in the Bioanalysis Plan).
Study Costs. Labcorp may deduct Study Costs from royalties and milestone fees owed to the extent permitted under Section 5.2.
